Clinical trial · Interventional
Survival Study of Docetaxel and Carboplatin as Neo-Adjuvant Vs Adjuvant Chemotherapy in Early Stage NSLC
Survival Study of Neo-adjuvant Versus Adjuvant Chemotherapy With Docetaxel Combined Carboplatin in Resectable Stage IB to IIIA Non-small Lung Cancer
NCT00321334CI-TRIAL-00015321completedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The objective of the trial is to determine whether 3 cycles of TP (docetaxel plus cisplatin) after complete operation will improve survival when compared with 3 cycles of TP prior to complete resection for NSCLC.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Chemotherapy+Surgery | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- ACTIVE_COMPARATOR
- label
- Docetexel
- description
- Chemotherapy+Surgery
- interventionNames
- Procedure: Chemotherapy+Surgery
Primary outcomes (1)
- measure
- 3 years Disease Free Survival (at end of 3 years)
- timeFrame
- Prospective
Secondary outcomes (1)
- measure
- 3 years Overall Survival rate (at end of 3 years) and Safety data (after third cycle finish)
- timeFrame
- Prospective
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically or cytologically confirmed stage IB-IIIA non-small cell lung cancer patients,without previous chemotherapy, radiotherapy or target-therapy; * age from 18 to 75; * PS with ECOC 0-1; * Adequate haematological and Hepatic- renal function; * Expected to live longer than 12 months; * The informed consent should be signed. Exclusion Criteria: * Patients with Small Cell Lung Cancer; * Already receiving any prior anti-cancer treatment; * Pregnant women; * Uncontrolled diabetes, mental disease; * Hepatic and renal function failure; * The investigators believe the patient is not suitable to be enrolled in the study
References
Publications (0)
Data not yet available
No reference posted for this study.